APIs
| No. | Prouduct name | CAS | Quality Standard | Therapy area | Status |
|---|---|---|---|---|---|
| 1 | Oseltamivir Phosphate | 204255-11-8 | CP/USP/EP | Anti-virotic | Commercial |
| 2 | Baloxavir marboxil | 1985606-14-1 | In House | Anti-influenza | Commercial |
| 3 | Tafamidis Meglumine | 951395-08-7 | CP | Neurological | Commercial |
| 4 | Flurbiprofen | 5104-49-4 | EP/USP/JP | Nonsteroidal anti-inflammatory | Commercial |
| 5 | S-Flurbiprofen | 51543-39-6 | CP | Nonsteroidal anti-inflammatory | Commercial |
| 6 | Dabigatran Etexilate Mesylate | 872728-81-9 | EP/BP | Cardiovascular | Commercial |
| 7 | Furosemide | 54-31-9 | EP/USP/JP | Gastrointestinal System | Commercial |
| 8 | Dexlansoprazole | 138530-94-6 | CP | Gastrointestinal System | Commercial |
| 9 | Granisetron | 109889-09-0 | EP/USP | CommercialGastrointestinal System | Commercial |
| 10 | Imrecoxib | 395683-14-4 | In House | Nonsteroidal anti-inflammatory | Commercial |
| 11 | Rotigotine | 99755-59-6 | EP/USP | Anti-Parkinson | Commercial |
| 12 | Deferasirox | 201530-41-8 | EP/BP | EP/BP | Commercial |
| 13 | Tetracaine | 94-24-6 | EP/USP | Local Anesthetic | Commercial |
| 14 | Tulobuterol | 41570-61-0 | JP | Anti-asthmatic | Commercial |
| 15 | Fosphenytoin Sodium | 92134-98-0 | USP | Anti-epileptic | Commercial |
| 16 | Lenalidomide | 191732-72-6 | CP/USP | Oncology | Commercial |
| 17 | Erlotinib hydrochloride | 183319-69-9 | CP/USP | Oncology | Commercial |
| 18 | Imatinib mesylate | 220127-57-1 | CP/USP | Oncology | Commercial |
| 19 | Sunitinib Malate | 341031-54-7 | CP/USP | Oncology | Commercial |
| 20 | Axitinib | 319460-85-0 | CP/USP | Oncology | Commercial |
| 21 | Ibrutinib | 936563-96-1 | CP/USP | Oncology | Commercial |
| 22 | Dasatinib | 302962-49-8 | CP/USP | Oncology | Commercial |
| 23 | Crizotinib | Crizotinib | CP/USP | Oncology | Commercial |
| 24 | Trametinib | 871700-17-3 | CP/USP | Oncology | Commercial |
| 25 | Sorafenib tosylate | 475207-59-1 | CP/USP | Oncology | Commercial |
| 26 | Lenvatinib | 417716-92-8 | CP/USP | Oncology | Commercial |
| 27 | Lapatinib ditosylate monohydrate | 388082-78-8 | CP/USP | Oncology | Commercial |
| 28 | Lenvatinib Mesilate | 857890-39-2 | CP/USP | Oncology | Commercial |
| 29 | Aprepitant | 170729-80-3 | CP/USP | Oncology | Commercial |
| 30 | Raltiturexed | 112887-68-0 | CP/USP | Oncology | Commercial |
| 31 | Regorafenib | 1019206-88-2 | CP/USP | Oncology | Commercial |
| 32 | Pazopanib Hydrochloride | 635702-64-6 | CP/USP | Oncology | Commercial |
| 33 | Bortezomib | 179324-69-7 | CP/USP | Oncology | Commercial |
| 34 | Ribociclib Succinate | 1374639-75-4 | In House | Oncology | R&D |
| 35 | Ticagrelor | 274693-27-5 | CP/USP | Anticoagulants | Commercial |
| 36 | Rivaroxaban | 366789-02-8 | USP/EP | Anticoagulants | Commercial |
| 37 | Lanthanum Carbonate | 6487-39-4 | In House | Metabolic disorders | Commercial |
| 38 | Avatrombopag Maleate | 677007-74-8 | In House | Blood disorders | Commercial |
| 39 | Idarubicin Hydrochloride | 57852-57-0 | CP/USP | Blood disorders | Commercial |
| 40 | Tolvaptan | 150683-30-0 | In House | Cardiovascular | Commercial |
| 41 | Olmesartan Medoxomil | 144689-63-4 | USP/EP | Cardiovascular | Commercial |
| 42 | Macitentan | 441798-33-0 | In House | Cardiovascular | Commercial |
| 43 | Mirabegron | 223673-61-8 | EP | Cardiovascular | Commercial |
| 44 | Tadalafil | 171596-29-5 | USP/EP | Cardiovascular | Commercial |
| 45 | Roxadustat | 808118-40-3 | In House | Cardiovascular | Commercial |
| 46 | Dapagliflozin | 461432-26-8 | USP | Cardiovascular | Commercial |
| 47 | Bisoprolol | 66722-44-9 | In House | Cardiovascular | R&D |
| 48 | Pemafibrate | 848259-27-8 | CP/USP | Hyperlipidemia | Commercial |
| 49 | C13 Urea | 58069-82-2 | CP | Diagnose Helicobacter pylori | R&D |
| 50 | Sofosbuvir | 1190307-88-0 | In House | Liver Diseases | Commercial |
| 51 | Tofacitinib Citrate | 540737-29-9 | In House | Autoimmune diseases | Commercial |
| 52 | Parecoxib Sodium | 198470-85-8 | In House | Anesthesia | Commercial |
| 53 | Dexmedetomidine Hydrochloride | 145108-58-3 | USP | Anesthesia | Commercial |
| 54 | Upadacitinib | 1310726-60-3 | In House | Rheumatoid Arthritis and Crohn | R&D |
| 55 | Lubiprostone | 333963-40-9 | In House | Other | Commercial |
| 56 | Sugammadex Sodium | 343306-71-8 | In House | Other | Commercial |
| 57 | Ruxolitinib Phosphate | 1092939-17-7 | In House | Other | Commercial |
| 58 | Obeticholic acid | 459789-99-2 | In House | Other | Commercial |
| 59 | Rosuvastatin Calcium | 147098-20-2 | USP/EP | Other | Commercial |
| 60 | Methylene blue | 61-73-4 | CP/USP/EP | Other | Commercial |
| 61 | Pemafibrate | 848259-27-8 | In House | Other | Commercial |
| 62 | Daraxonrasib | 2765081-21-6 | In House | Other | R&D |
| 63 | Crotamiton | 483-63-6 | USP/EP | Antiscabies | Commercial |
| 64 | Avobenzone | 70356-09-1 | USP | Ultraviolet absorber | Commercial |
| 65 | Octyldodecanol | 5333-42-6 | USP/EP | Lubricants、emulsifiers | Commercial |
| 66 | 2-Mercaptobenzimidazole | 583-39-1 | EP | Nonsteroidal anti-inflammatory drugs | Commercial |
| 67 | Hydrogenated palm glycerides | 91744-66-0 | In House | Non-ionic Surfactant | Commercial |
